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Background: The molecular principles governing T-cell specificity are poorly understood.
Results: High affinity binding of a melanoma-specific T-cell receptor (TCR) is mediated through new MHC contacts and
distinct thermodynamics.
Conclusion: A novel thermodynamic mechanism upholds TCR-peptide specificity.
Significance:TCRs canmaintain peptide specificity using amechanism thatmay enable widespread, safe enhancement of TCR
binding affinity in therapeutic applications.
The T-cell receptor (TCR) recognizes peptides bound to
major histocompatibility molecules (MHC) and allows T-cells
to interrogate the cellular proteome for internal anomalies from
the cell surface. The TCR contacts bothMHC and peptide in an
interaction characterized by weak affinity (KD 100 nM to 270
M). We used phage-display to produce a melanoma-specific
TCR (2417) with a 30,000-fold enhanced binding affinity
(KD  0.6 nM) to aid our exploration of the molecular mecha-
nisms utilized to maintain peptide specificity. Remarkably,
although the enhanced affinity was mediated primarily through
new TCR-MHC contacts, 2417 remained acutely sensitive to
modifications at every position along the peptide backbone,
mimicking the specificity of thewild typeTCR.Thermodynamic
analyses revealed an important role for solvation in directing
peptide specificity. These findings advance our understanding
of themolecularmechanisms that can govern the exquisite pep-
tide specificity characteristic of TCR recognition.
More than 30 different therapeutic monoclonal antibodies
(mAbs) have Food and Drug Administration approval, and
these soluble antigen receptors are being used in hundreds of
current clinical trials for a wide range of disease states ranging
from cardiovascular disease, cancer, and autoimmunity to
induction of transplant tolerance (1, 2). Therapeutic applica-
tion of the other class of antigen receptor, the T-cell receptor
(TCR),8 has lagged behind the progress made with mAbs, but
several recent studies have indicated that TCRs, or TCR/mAb
hybrid molecules, might have a very bright future in gene ther-
apy or as soluble molecules (3–5). TCRs have advantages over
mAbs as they can exploit the MHC class I (MHCI) peptide
presentation pathway to interrogate the internal proteome and
thereby access a much wider range of disease targets than are
available tomAbs. Antibodies undergo somatic hypermutation
and bind with strong affinity (KD nM–pM) and long half-lives
(typically hours). In contrast, TCRs are only naturally expressed
at the T-cell surface and bind foreign antigens with relatively
weak affinities (KD  100 nM to 270 M) and short half-lives
(0.1–12 s) (6, 7) with cancer-specific TCRs at the weaker end of
this scale (7, 8). The weak affinity and short half-lives of natural
TCR-pMHC interactions impose severe limitations on the
therapeutic use of TCRs as soluble molecules. Recently, molec-
ular engineering via phage display (5, 9, 10), yeast display (11),
and computational design (12, 13) have provided a route to
circumvent the intrinsic weak binding affinity of TCRs. Just a
few mutations within the TCR CDR loops can improve the
binding affinity of a TCR to antibody-like levels and beyond
(9–11). These developments have paved the way for the use of
enhanced TCRs as soluble therapies. Indeed, we have recently
shown that high affinity soluble “monoclonal” TCRs can be
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used to target cancer antigens at the cell surface and induce
tumor regression (14), and this approach is now being trialed at
several centers.
Despite the promise of affinity-enhanced TCRs, concerns
remain about their peptide specificity (15, 16). Complete
immune cover requires that a limited number of TCRs are able
to recognize the vastly greater number of potential foreign pep-
tides that could be encountered (17, 18). As a result, TCRs are
said to be “cross-reactive” or “poly-specific” (17, 19). The ability
of individual TCRs to recognize huge numbers of peptides has
raised significant concerns with regard to TCRs that have
undergone artificial affinity enhancement in vitro. These reser-
vations stem from the possibility that high affinity TCRs, par-
ticularly those where interaction between the TCR and the
MHC component have been increased, might recognize an
even greater number of cognate peptides. As enhanced TCRs
have not undergone thymic selection in vivo, there are concerns
that increased peptide cross-recognition by enhanced affinity
TCRs might extend to the binding of self-peptides with a high
enough affinity to induce off-target pathology. To date, there
has been no rigorous testing of the specificity of an enhanced
affinity TCR using molecular approaches.
Here we explored these issues using phage display to gener-
ate a high affinity TCR derived from theMEL5 TCR specific for
the heteroclitic version of the HLA-A*0201-restricted primary
melanoma antigen recognized by T-cells 1 (MART-126–35)
peptide, ELAGIGILTV (A2-ELA) (10, 20). This TCR, 2417,
bound to A2-ELA with an affinity 30,000 times stronger than
the natural parent MEL5 TCR, resulting in picomolar levels of
binding (10). Comparison of the crystallographic structure of
the2417TCRandwild typeMEL5TCR (21) in complexwith
A2-ELA showed that this remarkable enhancement in binding
was attributable to new or altered contacts with the MHC pro-
tein. Surprisingly though, 2417 remained exquisitely pep-
tide-specific, mimicking the specificity of the wild type recep-
tor. Structural and thermodynamic investigations highlighted
the role of solvent in determining peptide specificity, a novel
finding that sheds light on themolecular rules that govern TCR
specificity in general. Overall, we provide a new molecular
mechanism by which TCRs maintain peptide specificity and
show that it is possible to affinity mature TCRs for therapeutic
use as soluble molecules without concomitant loss of peptide
specificity.
EXPERIMENTAL PROCEDURES
Phage Display Selection of the High Affinity TCR, 2417—
Construction of the vector for displaying the wild type MEL5
TCR on the surface of phage was identical to previous reports
(10). The variable region of the TCR  (residues 25–100) and 
(residues 25–106) chains (including theCDR1, -2, and -3 loops)
was targeted for introducingmutations using primers that were
specific for the beginning of the TCR variable domain for each
chain. Mutations were introduced as previously described (10).
High affinityMEL5-derivedTCRswere selected by panning the
phage libraries on immobilized HLA-A2-ELAGIGILTV as pre-
viously reported (10), and the strongest binders were selected
for additional rounds of phage display. Thus, the 2417 TCR
was selected based only on its ability to bindwith high affinity to
HLA-A2-ELAGIGILTV.
Generation of Expression Plasmids—The 2417 TCR  and
 chains, HLA-A*0201 heavy chain and 2m chain were gen-
erated by PCR mutagenesis (Stratagene) and PCR cloning. All
sequences were confirmed by automated DNA sequencing
(Lark Technologies). The TCR sequences were constructed
implementing a disulfide-linked construct to produce the sol-
uble domains (variable and constant) for both the  (residues
1–207) and  chains (residues 1–247) (22, 23). The HLA-
A*0201 heavy chain (residues 1–248) (1,2, and3 domains),
tagged or not tagged with a biotinylation sequence, and 2m
(residues 1–100)were also cloned andused tomake the pMHCI
complexes. The TCR  and  chains, the HLA-A*0201  chain
and 2m sequences were inserted into separate pGMT7
expression plasmids under the control of the T7 promoter (22).
Protein Expression, Refolding, and Purification—Competent
Rosetta DE3 E. coli cells were used to produce the TCR  and 
chains,HLA-A*0201heavy chain, and2m in the formof inclu-
sion bodies using 0.5 mM isopropyl 1-thio--D-galactopyrano-
side to induce expression as described previously (22, 24, 25).
pMHCI Biotinylation—Biotinylated pMHCIwas prepared as
previously described (26).
Surface Plasmon Resonance (SPR) Experiments—SPR Equi-
librium binding analysis was performed using a BIAcore
T100TM equipped with a CM5 sensor chip as previously
reported (26–28). HLA-DR1, generated as in Cole et al. (29),
was used as a negative control on flow cell 1. SPR kinetic anal-
yses were carried out to determine theKD values for the TCR at
25 °C. For all kinetic experiments, 300 response units of
pMHCwere coupled to the CM5 sensor chip surface. The TCR
was then injected at concentrations ranging from 10 above
and 10 below the known KD of the interaction at 45 l/min.
The KD values were calculated assuming 1:1 Langmuir binding
(ABBABMAX/(KDB)), and the data were analyzed using
a global fit algorithm (BIAevaluationTM 3.1). SPR kinetic titra-
tion analysis was used to examine the binding of the 2417
TCR across a greater range of concentrations. The TCR was
analyzed at five concentrations that represented the maximum
range that could be accurately achieved around the KD of the
interaction. During the analysis,200 response units of pMHC
were immobilized onto the CM5 sensor chip surface. Each con-
centration of TCR was injected at a high flow rate of 45 l/min
for a 240-s association period and a 120-s dissociation period.
The final and highest concentration had a longer dissociation
period of 3600 s. A fast flow rate and a low amount of immobi-
lized pMHCwere used to limit the association and dissociation
mass transfer limitations as recommended by the experts at
BIAcoreTM. The kon, koff, and KD values were calculated by
global fitting of the data using BIAevaluationTM 3.1 software
and the single-cycle kinetics method (30). For the thermody-
namics experiments we used the KD determined by SPR at dif-
ferent temperatures with the standard thermodynamic equa-
tion G  RTlnKD and the standard non-linear Van’t Hoff
equation (G° H° TS° Cp°(T T0) TCp° ln(T/
T0)) with T0 298 K.
Thermodynamic Control of TCR Specificity
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Crystallization, Diffraction Data Collection, and Model
Refinement—All protein crystals were grown at 18 °C by vapor
diffusion via the sitting drop technique. 200 nl of 1:1molar ratio
TCR and pMHCI (10 mg/ml) in crystallization buffer (10 mM
Tris, pH 8.1, and 10 mMNaCl) was added to 200 nl of reservoir
solution. 2417 crystals were grown using our in-house TCR/
pMHC optimized protein crystallization screen (TOPS) in 0.1
M sodium cacodylate, pH 6.5, 20% PEG 8000, and 0.2 M ammo-
nium sulfate (31); 2417-A2-ELA crystals were grown in
TOPS4 in 0.1 M HEPES, pH 7.0, 20% PEG 4000, and 0.2 M
ammonium sulfate (31); 2417-A2-ELA4A crystals were
grown inTOPS3 in 0.1MTris, pH7.5, 15%PEG4000, and 17.4%
glycerol (31); 2417-A2-ELA7A crystals were grown in
TOPS4 in 0.1 M Bistris propane, pH 7.0, 20% PEG 4000, 0.2 M
ammonium sulfate, and 17.4% glycerol (31); A2-ELA1Acrystals
were grown in 25 mM MES, pH 6.5, 24% PEG 3350, and 10 mM
NaCl; A2-ELA4A crystals were grown in TOPS in 0.1 M sodium
cacodylate, pH6.0, 20%PEG8000, and 0.2M ammonium sulfate
(31); A2-ELA8A crystals were grown in 25 mM MES, pH 6.5,
24% PEG 3350, and 10 mM NaCl. All crystals were soaked in
30% ethylene glycol before cryo-cooling. All crystallization
screens and optimization experiments were completed using
anArt-Robbins Phoenix dispensing robot (Alpha Biotech Ltd.).
Data were collected at 100 K at the Diamond Light Source
(DLS), Oxfordshire, UK or the Advanced Photon Source at
Argonne National Laboratory. All datasets were collected at a
wavelength of 0.98 Å using an ADSC Q315 CCD detector.
Reflection intensities were estimated with the XIA2 package
(32), and the data were scaled, reduced, and analyzed with
SCALA and the CCP4 package (33). Structures were solved
with molecular replacement using PHASER (34). Sequences
were adjusted with COOT (35), and the models were refined
with REFMAC5. Graphic representations were prepared with
PyMOL (36). The reflection data and final model coordinates
were deposited with the PDB database (2417, PDB 4JFH;
2417-A2-ELA, PDB 4JFF; 2417-A2-ELA4A, PDB 4JFD;
2417-A2-ELA7A, PDB 4JFE; A2-ELA1A, PDB 4JFO;
A2-ELA4A, PDB 4JFP; A2-ELA8, PDB 4JFQ).
RESULTS
The 2417 TCR Binds to A2-ELA with High Affinity Due to
an ExtendedOff-rate—Togenerate a high affinity version of the
MEL5 TCR, we implemented phage display as previously
described (10). This process produced a high affinity TCR,
2417, that varied from the MEL5 TCR parental sequence at
19 amino acids located within the CDR1, CDR2, FW,
CDR3, CDR2, and CDR3 loops as well as in the  chain
between residues 41 and 45 (Fig. 1A). We previously demon-
strated that the wild type MEL5 TCR binds to A2-ELA with a
dissociation constant (KD) of 18 M (7, 20, 21) (Fig. 1B). The
high affinity 2417 TCR bound to A2-ELA with 30,000-fold
stronger affinity (KD  0.6 nM) (Fig. 1C) due primarily to a
slower off-rate of 1.09  104 s1. The off-rate for the MEL5
TCR was too fast to measure (0.1 s1) (Fig. 1B).
TheMEL5 and 2417 TCRs Use a Similar Binding Mode to
EngageA2-ELA—Previous structures of high affinityTCRs pro-
duced by phage display have shown that, although these
mutated TCRs can bind with many orders of magnitude stron-
ger affinity than their wild type progenitors, they bind with a
similar overall conformation (9, 37). This observation is impor-
tant because this conserved binding mode increases the likeli-
hood that high affinity-modified TCRs can maintain the rules
that govern T-cell antigen recognition and self-tolerance. To
determine the structural basis of high affinity binding for the
2417 TCR, we solved the 2417-A2-ELA complex struc-
ture to 2.4 Å. Molecular replacement was successful only in
space group P41, and the resolution was sufficiently high to
show that the interface between the two molecules was well
ordered and contained well defined electron density (supple-
mental Fig. S1). The crystallographic Rwork/Rfree factors were
21% and 26.3%, respectively. The ratio was within the accepted
limits shown in the theoretically expected distribution (38)
(supplemental Table S1). The overall buried surface area (BSA)
of 2705 Å2 (TCR-pMHC) for 2417-A2-ELA was slightly
higher than that for our previously published structure of
MEL5-A2-ELA (21) (BSA, 2327.8 Å2) (Table 1) but was within
the observed range for natural TCR-pMHC interactions (39).
The high affinity 2417 TCR bound with a diagonal docking
geometry to A2-ELA as previously reported for other TCR-
pMHC complexes (Fig. 2A) (39). We observed a high level of
similarity between the MEL5-A2-ELA and 2417-A2-ELA
complexes, suggesting that the overall conformation was not
substantially affected by themutations in2417. The crossing
angle of both TCRs (48° forMEL5 and 42° for 2417) (supple-
mental Fig. S2A) was similar and fell within the previously
observed range for TCR-pMHC complexes (39). The position-
ing of the complementarity-determining region (CDR)-loops
over the A2-ELA surface was also similar for both TCRs (sup-
plemental Fig. S2B). Importantly, the ELA peptide conforma-
FIGURE 1. Sequence and kinetic analysis of the HLA A2-ELAGIGILTV spe-
cific high affinity TCR, 2417. A, shown is sequence alignment of the
2417 TCR and the wild type MEL5 TCR progenitor. Mutations from the
MEL5 TCR wild type sequence are in bold and underlined. B and C, these data
were produced on a BIAcore T100TM using SPR and then analyzed using equi-
libriumanalysis (B) and kinetic titration analysis (C). Kinetic titration analysis is
an improved method for analyzing the kinetic parameters of high affinity
interactionswith long off-rates. Each TCRwas analyzed at five concentrations
that represented the greatest range we could accurately achieve around the
KD of each interaction, and the data were analyzed using the kinetic titration
analysis algorithm (BIAevaluationTM3.1) (30). The rawSPRdata and the fits are
shown in each panel. These data illustrate the improved binding capabilities
of the HLA A2-ELAGIGILTV-specific high affinity mutant TCR, 2417 (C). The
2417 TCRbound toHLAA2-ELAGIGILTVwith 30,000 times stronger affinity
compared to the MEL5 TCR.
Thermodynamic Control of TCR Specificity
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tion was virtually identical in both complexes, discounting the
possibility that changes in peptide structure contributed to the
affinity enhancement (supplemental Fig. 2, C and D). Thus,
differences in binding affinity between the MEL5 and 2417
TCRs could not be explained by a large conformational change
in geometry, in agreementwith our previously published obser-
vations (9, 37).
Increased TCR-MHC Interactions Underlie the High Affinity
Binding of the 2417 TCR—Previous structures of high affin-
ity TCRs have shown that just a small number of additional
contacts at the binding interface can mediate huge improve-
ments in TCR binding affinity (9, 37). To delineate the mecha-
nism behind the high affinity binding of the 2417 TCR, we
investigated the binding interface in atomic detail. Although
the overall conformations of the MEL5 and 2417 TCRs in
complex with A2-ELA were comparable, there were a number
of important interfacial differences that could explain the
divergent binding affinities. The interactions with the
ELAGIGILTV peptide were very similar for MEL5 and 2417
TCRs, making 39 and 42 contacts, respectively (Table 1). How-
ever, the 2417 TCR utilized a substantial number of new
contacts with the MHC surface, making 97 MHC contacts
comparedwith only 56 forMEL5 (Table 1, Fig. 2,B andC). This
increase in interactions with the MHC was consistent with the
increased BSA for 2417-A2-ELA (Table 1) and was probably
the main mechanism enabling 2417 to bind with an affinity
30,000-fold stronger than MEL5 to A2-ELA. The majority of
the new contacts were directly attributable to the mutated res-
idues in the 2417 TCR. For instance, MEL5 TCR chain
residue Asp-27made no contacts with theMHC surface. How-
ever, whenmutated in the 2417 TCR chain, the longer aro-
matic side chain of residue Phe-27 was able to make four vdW
contacts with MHC residue Glu-58 (supplemental Table S2,
Fig. 3A). Similarly, the mutation from MEL5 TCR chain resi-
due Val-93 to Asp-93 in the 2417 TCR chain resulted in
four new vdW contacts and two new hydrogen bonds, and the
mutation from MEL5 TCR chain residue Ile-53 to Phe-53 in
the2417 TCR chain resulted in 18 new vdWcontacts and 1
new hydrogen bond (supplemental Table S2, Fig. 3). Overall,
mutated residues in the 2417 TCR accounted for 36 new
vdW contacts and 3 new hydrogen bonds with the MHC sur-
face (supplemental Table S2). Thus, the vast majority of the 44
new contacts formed by the2417TCRweremade directly by
mutated residues with only a small number of new contacts
made through indirect effects of the high affinity mutations on
non-mutated residues (Table 1, supplemental Table S3). Our
observation, that the 2417 TCR mediated enhanced affinity
through an increase in MHC contacts, substantially altered the
ratio of TCR-peptide contacts versusTCR-MHCcontacts com-
pared with MEL5. For instance, the MEL5 TCR made 41% of
the total contacts with the peptide, compared with just 30% for
the 2417 TCR. This change in focus, from peptide interac-
tions to MHC interactions, raised the possibility that the
2417 TCRmight bind in a peptide-independent manner. To
FIGURE 2. Structural analysis of the bindingmode implementedbyMEL5
versus2417when interactingwithA2-ELA.A, shown is the overall bind-
ing mode of MEL5 (data are from our previously published work (21)) (green
schematic) and 2417 (cyan schematic) interaction with HLA-A*0201 (gray
schematic) and the ELAGIGILTV peptide (yellow sticks). Generally, the two
TCRsbind in a very similar orientation,with somedifferences in theCDR loops
andmore flexible regions of the TCR variable and constant domains. B and C,
a surface representation of the A2-ELA complex looking down at the peptide
is shown. MHC residues that are contacted by the TCR are colored in red.
Peptide residues that are contacted by the TCR are colored yellow. From this
analysis, it is clear that although MEL5 (B) and 2417 (C) make a similar
contact footprintwith thepeptide (yellow),2417makes substantiallymore
interactions with the MHC surface (red).
TABLE 1
Summary of co-complex structures of 2417-A2-ELA, 2417-A2-ELA4A, and 2417-A2-ELA7A
Parameter MEL5-A2-ELA 2417-A2-ELA 2417-A2-ELA4A 2417-A2-ELA7A
H-bonds (3.2 Å) 6 16 15 16
H-bonds (3.4 Å) 1 6 6 1
vdW (3.5 Å) 23 21 11 15
vdW (4 Å) 65 95 109 105
Total contacts 95 138 141 136
CDR1/CDR2/CDR3 contacts (4Å)
 chain 26/11/13 37/12/21 38/16/18 31/8/20
 chain 3/6/36 1/38/30 1/41/27 1/46/30
Peptide contacts 39 42 39 41
MHC contacts 56 97 102 95
Crossing angle 42° 48° 48° 48°
Buried surface area (Å2) 2327.8 2705 2650.4 2781.6
Surface complementarity
TCR-MHC 0.55 0.71 0.65 0.66
TCR-peptide 0.71 0.59 0.58 0.62
TCR-pMHC 0.6 0.66 0.62 0.63
Thermodynamic Control of TCR Specificity
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investigate this possibility further, we probed the ability of
2417 to tolerate substitutions in the ELAGIGILTV peptide.
The 2417 TCR Remains Highly Sensitive to Peptide
Substitutions—The 2417-A2-ELA structure demonstrated
that new MHC contacts were central to the 30,000-fold stron-
ger affinity compared with the MEL5-A2-ELA complex. This
enhancement did not enable 2417 to bind to other HLA-A2-
restricted peptides that were used as negative controls in
different SPR experiments, including A2-ILAKFLHWL, A2-
SLLMWITQC, and A2-YLEPGPVTA (data not shown). We
then investigated the ability of 2417 to tolerate changes in
the cognate ELAGIGILTV peptide by performing an alanine
mutagenesis scan across the peptide backbone and evaluating
the capacity of the A2-ELAmutants to bind 2417 using SPR
(Table 2, supplemental Fig. S3). As peptide positions P2 and
P10were buried and are known to be important forMHCbind-
ing (40), we focused on assessing the adjacent residues at posi-
tions P1, P4, P5, P6, P7, P8, and P9. We omitted P3, as this
residue is already Ala in the native sequence. Strikingly, modi-
fication of any peptide residue to Ala reduced the binding of
2417 towild type-like affinities or lower (Table 2). For exam-
ple,2417 boundA2-ELAwithGly substituted forAla at posi-
tion 4 (A2-ELA4A) with a KD of 36 M, 60,000-fold weaker
affinity than for A2-ELA (G°  6.51 kcal/mol) (Table 2). In
the 2417-A2-ELA structure, four hydrogen bonds and eight
vdWcontacts weremade between the TCR and peptide residue
Gly-4 (supplemental Table S3). Thus, although Ala and Gly are
similar in terms of size and charge, this mutation could poten-
tially result in the disruption of an important network of TCR-
peptide contacts. Similarly, 2417 bound A2-ELA with Ile
substituted for Ala at position 7 (A2-ELA7A), which resulted in
a KD of 31 M, 50,000-fold weaker affinity than for A2-ELA
(G° 6.42 kcal/mol) (Table 2). The 2417-A2-ELA struc-
ture showed that three hydrogen bonds and eight vdWcontacts
weremade between the TCR and peptide residue Ile-7 (supple-
mental Table S3). Thus, the reduction in binding affinity
observed for 2417 binding to the Ala-7 mutant could be
attributed to a disruption of TCR-peptide contacts. Substitu-
tion of Ala for Ile at P5 in the peptide abrogated binding to
undetectable levels (Table 2). The 2417-A2-ELA structure
showed that only 4 vdW contacts were made between 2417
and the peptide residue Ile-5. Thus, the observed effect on bind-
ing affinity was surprising and was likely due to indirect effects
on TCR binding.
Importantly, the MEL5 TCR was also very sensitive to Ala
substitutions, and we observed no binding to the MEL5 TCR
with Ala substituted across the ELAGIGILTV peptide (data not
shown). These data demonstrate that, even though the 2417
TCR bound with a KD of 0.6 nM, mediated by new contacts
made with the MHC, the TCR was still extremely sensitive to
changes in the antigenic peptide.
Peptide Substitutions Do Not Alter the Overall Conformation
of the 2417-A2-ELA Complex—As the enhanced affinity of
the 2417 TCR could largely be attributed to increased con-
tacts between the TCR andMHC, the exquisitemaintenance of
peptide specificity we observedwas surprising. Indeed, Ala sub-
stitutions in the peptide were predicted to have the potential to
directly disrupt only a small number of TCR-pMHC contacts
and were, therefore, expected to have a limited impact on bind-
ing affinity. To gain a more detailed atomic perspective on this
unexpected and dramatic observation, we solved the co-com-
plex structures of two alanine-substituted ligands where there
was residual binding by the 2417 TCR. Co-complexes of
2417 with A2-ELAAIGILTV (A2-ELA4A) and A2-ELAGI-
GALTV (A2-ELA7A) enabled a detailed view of the atomic
bonding between these antigens and TCR. The 2417-A2-
ELA4A and 2417-A2-ELA7A complex structures were
solved to a resolution of 2.5 and 2.7 Å, respectively. Molecular
replacement was successful only in space group P41 for both
complexes, and the resolutionwas sufficiently high to show that
the interface between the two molecules was well ordered and
contained well defined electron density (supplemental Fig. S1).
FIGURE 3. The 2417-mutated residues make an increased number of
contacts with the MHC surface compared with MEL5 wild type residues.
MEL5 residues are shown on the left-hand side of each panel in green. The
equivalent2417 residues are shown on the right-hand side of each panel in
cyan. Hydrogen bonds (3.4 Å) are shown as red dotted lines and van der
Waals interactions (4.0 Å) are shown as black dotted lines. In all cases an
increased number of interactions was observed between 2417 and the
MHC surface compared with MEL5. Shown are position 27 in the TCR CDR1
loop (A), position 52 in the TCR CDR2 loop (B), position 93 in the TCR
CDR3 loop (C), position 96 in the TCR CDR3 loop (D), position 52 in the TCR
CDR2 loop (E), and position 53 in the TCR CDR2 loop (F).
TABLE 2
Kinetic binding analysis of 2417 to alanine-substituted peptides
NM, not measured. NB, no binding.G°G° of 2417-A2-alanine variants
G° of 2417-A2-ELAGIGILTV.
TCR Peptide Peptide sequence Affinity -KD G° G°
kcal/mol kcal/mol
MEL5 ELA ELAGIGILTV 18 M 6.5 NM
2417 ELA ELAGIGILTV 600 pM 12.57 NM
ELA1A ALAGIGILTV 140 M 5.25 7.32
ELA4A ELAAIGILTV 36 M 6.06 6.51
ELA5A ELAGAGILTV NB NM NM
ELA6A ELAGIAILTV 41 M 5.98 6.59
ELA7A ELAGIGALTV 31 M 6.15 6.42
ELA8A ELAGIGIATV 21 M 6.38 6.19
ELA9A ELAGIGILAV 37 M 6.04 6.53
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The crystallographicRwork/Rfree factors were 20.2 and 24.8% for
2417-A2-ELA4A, respectively, and 20.2 and 25% for
2417-A2-ELA7A, respectively (supplemental Table S1).
Comparedwith the2417-A2-ELA structure, the overall BSA
was very similar across the three co-complex structures
(2417-A2-ELA BSA 2705 Å2, 2417-A2-ELA4A BSA
2650.4 Å2, 2417-A2-ELA7A BSA  2781.6 Å2) (Table 1).
Additionally, the docking geometry and the positions of the
TCR CDR loops were indistinguishable between the three co-
complexes (Table 1, Fig. 4). Thus, large conformational changes
could not explain the large difference in binding affinity
between 2417-A2-ELA and the Ala mutants.
Peptide Substitutions Do Not Directly Alter Contacts between
the 2417 TCR and A2-ELA—To further dissect the effects of
the Ala substitutions on 2417 binding, we investigated the
direct consequences of these mutations on binding. The struc-
ture of 2417 bound to A2-ELA demonstrated that peptide
residue Gly-4 made four hydrogen bonds and eight vdW con-
tacts, and Ile-7 made three hydrogen bonds and eight vdW
contacts with the TCR (Fig. 5,A and B, and supplemental Table
S3). The 2417-A2-ELA4A structure revealed that the num-
ber of contacts was comparable between peptide residue Ala-4
and 2417 (3 hydrogen bonds and 10 vdW contacts), and the
2417-A2-ELA7A structure showed that the number of con-
tacts was also very similar between peptide residue Ala-7 and
2417 (two hydrogen bonds and eight vdW contacts) (Fig. 5,
C and D, and supplemental Tables S4 and S5). Thus, it was
unlikely that changes in contacts in the Ala peptide substitu-
tions could directly explain the 50,000-fold difference in
binding affinity between 2417 binding to A2-ELA compared
with A2-ELA4A and A2-ELA7A.
Peptide Substitutions Do Not Alter the Overall Conformation
of Unligated A2-ELA Molecules—We next explored the possi-
bility that Ala substitutions could impact TCR binding by alter-
ing the structure of the unligated A2-ELA molecules. We rea-
soned that, if 2417 TCR binding required a conformational
shift in the peptide, then more energy would be required to
reach the same final bound state, thus explaining the lower
binding affinity. To this end we solved the atomic structures of
A2-ELA1A, A2-ELA4A, and A2-ELA8A at 2.1, 1.9, and 1.9 Å
resolution, respectively (supplemental Table S6). Molecular
replacement was successful in space groups P1, C121, and
P1211 forA2-ELA1A,A2-ELA4A, andA2-ELA8A, respectively,
and the resolution was sufficiently high to show that the struc-
tures were well ordered and contained well defined electron
density (supplemental Fig. S1). A comparison of these Ala
mutant structures with the unligated structure A2-ELA (41)
showed that each mutant did not substantially alter its struc-
ture when in complexwith TCR (21, 42) (supplemental Fig. S4).
These data discounted the possibility that alterations in the
unligated conformation of the Ala-substituted A2-ELA pep-
tides could explain the sensitivity of the 2417 TCR to these
single peptide mutations. Collectively, the detailed structural
analysis of 2417 TCR binding to A2-ELA and alanine substi-
tutions thereof did not provide a clear explanation for the
observed peptide specificity of 2417 TCR binding.
Peptide Specificity Is Governed by Altered Entropy and a
Reduction inWater Bridges—We next asked to what extent the
striking peptide specificity of 2417 could be explained by
thermodynamics. This was achieved by comparing the changes
FIGURE 4. Structural comparison of the binding mode implemented by
2417 when interacting with A2-ELA, A2-ELA4A, and A2-ELA7A.
A2-ELA is shown in a gray schematic, and peptide is shown as yellow sticks. A,
shown is the overall binding mode of 2417 when interacting with A2-ELA
(cyan schematic), A2-ELA4A (red schematic), and A2-ELA7A (orange sche-
matic). 2417 binding in a virtually identical mode to all three epitopes is
shown. B and C, shown are surface representations of the A2-ELA complex
(colored as in A) looking down at the peptide. B, positions of the 2417 TCR
CDR loops when interacting with A2-ELA (cyan schematic), A2-ELA4A (red
schematic), and A2-ELA7A (orange schematic) are shown. C, shown is the
2417 TCR crossing angle when interacting with A2-ELA (cyan schematic),
A2-ELA4A (red schematic), and A2-ELA7A (orange schematic). The positions of
the CDR loops and the TCR crossing angle are virtually identical across all
three complexes.
FIGURE 5. Interactions between 2417 and modified residues in the
ELAGIGILTV peptide at positions 4 and 7. Hydrogen bonds (3.4 Å) are
shown as red dotted lines, van der Waals interactions (4.0 Å) are shown as
black dotted lines, and water molecules are shown as gray spheres. Shown are
2417 (cyan sticks) interactionswithpeptide residues (yellow sticks) Gly-4 (A)
and Ile-7 (B). C, shown is 2417 (red sticks) interacting with A2-ELA4A, resi-
due Ala-4 (red sticks). D, shown is 2417 (orange sticks) interacting with
A2-ELA7A, residue Ala-7 (orange sticks). Contacts between 2417 and the
three epitopes (A2-ELA, A2-ELA4A, and A2-ELA7A) are virtually identical and
cannot explain the reduced affinity between 2417 and the modified
peptides.
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in enthalpy (H°) and entropy (TS°) of 2417 binding to
A2-ELA and the Ala peptide variants (Fig. 6, supplemental Figs.
S5–S7). The 2417-A2-ELA interaction (Fig. 6A) was
entropically driven (TS°  18.1 kcal/mol) and enthalpically
unfavorable (H° 6 kcal/mol), within the range observed for
other TCR-pMHC interactions (from30 to 18 kcalmol1 for
H° and from 80 to 24 kcalmol1 for TS°) (43, 44). The
structure of the unligated 2417 TCR (supplemental Table
S1) demonstrated that a large 8.06 Å conformational shift in
CDR3 loopwas required to accommodate residues toward the
C terminus of the peptide (supplemental Fig. S8). Together
with the observation of a favorable entropy change for binding,
these observations indicated that, similar to theMEL5-A2-ELA
complex (TS°  8.3 kcal/mol) (21), an entropically favorable
transition from order to disorder was key for driving the high
affinity interaction, probably through the expulsion of ordered
solvent during binding rather than a loss of order at the TCR-
pMHC interface. This energetic mechanism was reversed for
the 2417-A2-ELA4A and 2417-A2-ELA7A interactions,
both binding with unfavorable entropy (TS°9.8 and0.5
kcal/mol, respectively), and favorable enthalpy (H°  15.6
and5.9 kcal/mol, respectively) (Fig. 6,B andC). Thus, the loss
of binding affinity observed for the interaction between the
2417 TCR and the Ala-modified peptides seemed to be gov-
erned by a change in the order-disorder balance during binding,
possibly due to differences in the interaction between the unli-
gated molecules and solvent (44). Furthermore, although
2417 bound to A2-ELA4A (KD  36 M) and A2-ELA7A
(KD 31M)with affinities similar to theMEL5-A2-ELA inter-
action (KD  18 M), 2417 used a distinct thermodynamic
signature (favorable enthalpy) compared with MEL5-A2-ELA
(favorable entropy). Our observations that single Alamutations
cause a substantial differences in energetic binding underscore
the exquisite sensitivity of this high affinity TCR to interfacial
perturbations.
We then examined the role of water molecules during anti-
gen recognition and noticed changes in the number of water
bridges between the different complexes. For instance, in the
2417-A2-ELA complex, nine water bridges were formed
between the TCR and pMHC compared with only seven for
2417-A2-ELA4A and five for 2417-A2-ELA7A (Fig. 7).
Although the reduction in water bridge-mediated hydrogen
bonds could partly explain the reduction in binding affinity to
the Ala-substituted peptide mutants, the difference in water
bridges also suggested that the interaction between the TCR/
pMHC/solvent was different in the three complexes. Here, the
less favorable entropic values that were the main driving force
governing theweaker binding affinity observed for the2417-
A2-ELA4A and 2417-A2-ELA7A interactions were most
likely due to a reduction in the expulsion of ordered solvent
during binding. We conclude that the reordering of solvent
during antigen engagement provides the best explanation for
the sensitivity of the TCR to peptide side-chain substitutions,
considering the similar bindingmodes and the distinct thermo-
dynamic signatures observed for the 2417 TCR interacting
with A2-ELA compared with A2-ELA4A and A2-ELA7A.
Overall, these data support the idea that TCR specificity can be
mediated by changes in solvent interactions between the TCR
and pMHC that can occur through a “knock-on” effect due to
modifications to the peptide sequence.
DISCUSSION
The clonotypic TCR, expressed on the surface of CD8
T-cells, allows recognition of peptide fragments from endoge-
nous proteins presented at the cell surface by MHCI. TCRs
discriminate between peptides and permit T-cell-mediated
elimination of any cell expressing potentially dangerous intra-
cellular proteins. Exploitation of the TCR offers exciting new
possibilities for disease-specific therapies. Unlike antibodies
that bind with a relatively strong affinity, TCRs bind with a
weak affinity (KD  100 nM to 270 M) and short half-lives
(0.1–12 s) (6, 7). This disparity is magnified during cancer-spe-
cific T-cell responses due to self-specific TCRs binding at the
weaker end of this scale (7). The weak affinity and short half-
lives of natural TCR-pMHC interactions impose severe con-
straints on the use of soluble TCRs for targeting cell surface-
FIGURE 6. Thermodynamic analysis of 2417 binding to A2-ELA,
A2-ELA4A, andA2-ELA7A. The thermodynamic parameterswere calculated
according to the Gibbs-Helmholtz equation (G°H TS°). The binding
free energies, G° (G°  RTlnKD), were plotted against temperature (K)
using non-linear regression to fit the three-parameter Van’t Hoff equation
(RTln KD H° TS° Cp°(T T0) TCp° ln(T/T0) with T0 298 K) as
previously reported (24). Thermodynamicmeasurements of 2417 binding
to A2-ELA (A), 2417 binding to A2-ELA4A (B), and 2417 binding to
A2-ELA7A (C) are shown. 2417 uses a distinct thermodynamic strategy
when binding to each of the three different epitopes.
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expressed pMHCs. This limitation has recently been overcome
using phage display (10), yeast display (11), and computational
design (12, 13) techniques that enhance TCR affinity by vastly
extending the half-life of TCRs for cognate pMHC. These new
developments enable cellular targeting of diseased tissue with
enhanced TCR in soluble form (17).
We previously generated several high affinity TCRs directed
against a range of antigens using phage display and directed
evolution (5, 10, 14). Here, we investigated the interaction of
one of these mutants, 2417, derived from the MEL5 TCR
that is specific for the HLA-A*0201-restricted MART-126–35
antigen (45). The 2417 TCR bound to A2-ELAwith an affin-
ity 30,000 times stronger than the MEL5 TCR (10), primarily
attributed to a longer off-rate. To better understand the mech-
anism of high affinity TCR binding, we solved the structure of a
high affinity TCR, 2417, in complex with A2-ELA. Although
2417 used a similar overall binding mode to MEL5 during
engagement, finer examination of the structure demonstrated
just three new contacts between 2417 and the ELA peptide,
compared with 41 new MHC contacts. Thus, the enhanced
affinity wasmediated primarily through additional interactions
with the surface of theMHCmolecule. This observation raised
the possibility that the2417TCRmight exhibit reduced pep-
tide specificity, an outcomewith significant implications for the
development and widespread use of high affinity TCRs. To
investigate the peptide specificity of 2417, we performed an
investigation of Ala substitutions across the peptide backbone.
Other investigations have shown that peptide substitutions can
have a range of effects onTCRbinding.Usually, substitutions in
the center of the peptide have the largest effect onTCRbinding,
whereas substitutions at the ends of the peptide have a smaller
or no effect (46–48). Surprisingly, we observed that the2417
TCR was highly sensitive to single Ala substitutions at all posi-
tions in the peptide with somemutations capable of completely
abrogating binding.
Although the finding that 2417 was highly sensitive to
single Ala peptide mutations could be system-specific (i.e.may
not be observed for other high affinityTCRs), it was unexpected
and warranted further investigation into the molecular mecha-
nisms underlying this effect.We solved the structure of2417
in complex with two Ala mutants, A2-ELA4A and A2-ELA7A.
Additionally, we solved the structure of the unligated 2417
TCR and unligated A2-ELA1A, A2-ELA4A, and A2-ELA8A
molecules. Collectively, the structures demonstrated that the
2417 used an almost identical binding strategy to engage
the Ala mutants compared with the native A2-ELA and that
the Ala mutations did not alter the peptide conformation
of the unligated pMHCs. The total number of contacts made
in the 2417-A2-ELA complex was similar to the mutated
2417-A2-ELA4A and 2417-A2-ELA7A complexes and
could not explain the substantially weaker binding affinity to
the 2417 TCR.
Previous analyses have shown TCRs can use a range of dif-
ferent thermodynamic strategies to bind to pMHC, although
favorable enthalpy,most likelymediated through the formation
of new bonds during ligation, is themost common driving force
(43). This energetic diversity reflects the flexible binding strat-
egies implemented by the TCR during pMHC engagement.
Although conformational plasticity in the TCR CDR loops
upon pMHC binding is the most common mechanism
deployed (48–50), a number of studies have also shown that the
TCR can remain rigid (42, 46, 51–53), enabling a “lock and
key”-like interaction. A thermodynamic investigation of
2417 binding to A2-ELA, compared with A2-ELA4A and
A2-ELA7A, generated some highly unanticipated results. The
2417 TCR used a distinct thermodynamic signature to
engageA2-ELA comparedwithA2-ELA4A andA2-ELA7A (we
observed a marked decrease in favorable entropy for 2417
binding to A2-ELA4A and A2-ELA7A). This entropy drop sug-
gested that differences in the ordering of solvent molecules
involved during 2417 binding could have an important role
in governing antigen specificity. In support of this notion, we
observed a reduction in the number of water bridges for
2417 binding to A2-ELA4A and A2-ELA7A compared with
A2-ELA. These data support the idea that peptide specificity
can be mediated almost solely through changes in solvent.
In summary, we show that major improvements to TCR
affinity can be gained by increasing interactions between the
TCR and theMHC.Despite predictions to the contrary (15, 16),
however, such an outcomeneed not abrogate the exquisite pep-
tide specificity characteristic of TCR recognition. Our biophys-
ical and thermodynamics analyses of the 2417 TCR suggest
that altered interactions with solvent molecules were themajor
contributor to the maintenance of peptide specificity. This
FIGURE 7. 2417 makes more water bridges with A2-ELA compared
with A2-ELA4A and A2-ELA7A. 2417 binding to A2-ELA is shown in cyan
sticks, and peptide is shown in yellow sticks. 2417 binding to A2-ELA4A is
shown in red sticks, andpeptide is in red sticks.2417binding toA2-ELA7A is
shown in orange sticks, and peptide is in orange sticks. The MHC is shown in a
gray schematic, and water molecules are shown as gray spheres. Hydrogen
bonds (3.4 Å) are shown as red dotted lines. Shown are water bridges in the
2417-A2-ELA complex between the TCR and peptide (A), water bridges in
the 2417-A2-ELA4A complex between the TCR and peptide (B), water
bridges in the 2417-A2-ELA7A complex between the TCR and peptide (C),
water bridges in the 2417-A2-ELA complex between the TCR and MHC1
helix (D), water bridges in the 2417-A2-ELA4A complex between the TCR
and MHC1 helix (E), water bridges in the 2417-A2-ELA7A complex
between the TCR and MHC1 helix (F), water bridges in the 2417-A2-ELA
complexbetween the TCRandMHC2helix (G), water bridges in the2417-
A2-ELA4A complex between the TCR andMHC2 helix (H), andwater bridges
in the 2417-A2-ELA7A complex between the TCR and MHC2 helix (I).
Thermodynamic Control of TCR Specificity
JUNE 28, 2013•VOLUME 288•NUMBER 26 JOURNAL OF BIOLOGICAL CHEMISTRY 18773
 by guest on A
ugust 8, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
observation broadens our understanding of T-cell antigen rec-
ognition and provides a newmechanism by which TCRs main-
tain peptide specificity.
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Supplementary Table S1. Data collection and refinement statistics for unligated α24β17 TCR and 
complex structures  
 
 α24β17 α24β17-A2-ELA α24β17-A2-ELA4A α24β17-A2-ELA7A 
PDB Code 4JFH 4JFF 4JFD 4JFE 
Data collection     
Space group P3221 P41 P41 P41 
Cell dimensions     
    a, b, c (Å) 97.14, 97.14, 123.08 121.44, 121.44, 82.3 121.49, 121.49, 82.96 121.52, 121.52, 82.15 
()  90, 90, 120 90, 90, 90 90, 90, 90 90, 90, 90 
Resolution (Å) 49.7-2.4 (10.7-2.4) 68.1-2.5 (10.9-2.4) 54.3-2.5 (11.0-2.5) 54.4-2.7 (11.8-2.6) 
Rmerge (%) 19.2  9.1  7.3  10.3 
I /  16.6  14.8  17.1  13.5  
Completeness (%) 100  100  100  99.9 
Redundancy 10.9  8.3  8.2  8.1 
     
Refinement     
Resolution (Å) 2.4 2.4 2.5 2.7 
No. reflections 25403 42931 41936 31318 
Rwork / Rfree 20.1/24.6 21/26.3 20.2/24.8 20.2/25 
No. atoms 3694 6874 6820 6765 
    Protein 3492 6650 6629 6667 
    Ligand/ion 41 65 66 32 
    Water 161 159 125 66 
B-factors 44.63 54.73 68.38 62.91 
    Protein 44.60 54.74 68.91 62.91 
    Ligand/ion 60.79 85.12 59.51 110.62 
    Water 41.10 41.68 44.75 40.31 
R.m.s. deviations     
    Bond lengths (Å) 0.022 0.021 0.021 0.019 
    Bond angles () 1.206 1.246 1.174 1.134 
* One crystal was used for solving each structure. *Values in parentheses are for highest-resolution shell. 
 
  
Supplementary Table S2. Direct contacts made by the wild type, or mutant TCR residues 
 
 TCR residue vdW (≤4 Å) H-bonds (≤3.4 Å) 
Wild type αAsp27 0 0 
MEL5 TCR αArg28 2 MHC 1 MHC 
 αSer52 0 0 
 αVal93 0 0 
 αAla94 6 MHC 1 MHC 
 αLys96 2 MHC 0 
 βVal51 4 MHC 0 
 βGly52 0 0 
 βIle53 0 0 
 βThr100 7 MHC 1 MHC 
Total  21 3 
Mutant αPhe27 4 MHC 0 
α24β17 TCR αLeu28 5 MHC 0 
 αArg52 3 MHC 0 
 αAsp93 4 MHC 2 MHC 
 αGly94 6 MHC 1 MHC 
 αArg96 7 MHC 0 
 βGly51 3 MHC 0 
 βPro52 4 MHC 1 MHC 
 βPhe53 18 MHC 1 MHC 
 βMet100 2 MHC 1 ELA 1 MHC 
Total  68 6 
 
 
  
Supplementary Table S3: α24β17-A2-ELA contacts (residues mutated from MEL5 shown in red) 
Peptide  TCR H-bonds (≤3.2Å) H-bonds (≤3.4Å) vdW (≤3.5Å) vdW (≤4Å) 
Glu1Oε2/H2O αGly29O/H2O 1 1  2 
Glu1H2O αGln31H2O  1  2 
Leu2O αGln31Nε2 1   1 
Ala3 αGln31    2 
Ala3 βLeu98   1  
Gly4N αGln31Oε1 1  2 3 
Gly4H2O αSer32H2O 1 1   
Gly4H2O αAsn92H2O 1    
Gly4 βLeu98    2 
Ile5 αTyr51    1 
Ile5 βLeu98   2  
Ile5 βMet100    1 
Gly6N βLeu98O 1    
Ile7 βGly97   2  
Ile7N/O βLeu98O/N 2   6 
Leu8 βGly99    1 
Thr9 βThr96    2 
MHC  TCR  H-bonds (≤3.2Å) H-bonds (≤3.4Å) vdW (≤3.5Å) vdW (≤4Å) 
Glu58 αPhe27    4 
Gly62 αAsp93    1 
Arg65 βIle56    2 
Arg65NH2 αAsp93O 1   3 
Arg65Nε αGly94O 1  2 3 
Arg65 αArg96    7 
Lys66H2O αGly29H2O 1    
Lys66H2O αGly31H2O  1  1 
Lys66H2O αAsp93H2O 1    
Lys66 αGly94    1 
Ala69 βTyr49    1 
Ala69 βIle56    2 
Ala69 βLeu98    1 
His70 βLeu98    2 
Gln72 βGly51   2 1 
Gln72Oε1 βPro52N 1  1 3 
Gln72Oε1 βPhe53N 1   4 
Gln72Nε2 βGly54O  1   
Gln72 βIle56    2 
Thr73 βGly97   2  
Arg75 βPhe53   2 11 
Val76 βAsn30   1  
Val76 βPhe53    3 
Glu154 αTyr51   1 2 
Gln155 αTyr51    3 
Gln155 βGly99    1 
Gln155H2O βMet100H2O 1   2 
Arg157 αArg52   1 2 
Ala158 αTyr51    2 
Tyr159 αGln31   1  
Thr163H2O αGln31H2O 1   2 
Thr163 αLys66Nζ  1   
Trp167 αLeu28    3 
Trp167 αGly29    2 
Arg170 αLeu28   1 1 
 
Supplementary Table S4: α24β17-A2-ELA4A contacts (4A peptide contacts shown in red) 
 
Peptide  TCR  H-bonds H-bonds vdW vdW 
Glu1Oε2/H2O αGly29O/H2O 1 1  2 
Glu1Oε2 αGln31Nε2  1 2 
Leu2O αGln31Nε2 1 1 
Ala3 αGln31  2 
Ala4N αGln31Oε1 1 6 
Ala4H2O αSer32H2O 1  
Ala4H2O αAsn92H2O  1  
Ala4 βLeu98  2 
Ile5 αTyr51  1 
Ile5 βLeu98  2  
Ile5 βMet100  1 
Gly6N βLeu98O  1  
Ile7 βGly97  2  
Ile7N/O βLeu98O/N 2 7 
Thr9 βThr96  1  
MHC  TCR  H-bonds H-bonds vdW vdW 
Glu58 αPhe27    4 
Gly62 αAsp93  1 
Arg65 βIle56  2 
Arg65NH2 αAsp93O/Oδ2 1 1SB 3 
Arg65 αArg96  8 
Lys66H2O αGly29H2O 1  
Lys66 αGln31  1 
Lys66 αGly94  3 
Lys68H2O βIle56H2O 1  
Ala69 βTyr49  1 
Ala69 βLeu98  2 
His70 βLeu98  1 
Gln72 βGly51  2 1 
Gln72Oε1 βPro52N 1 1 3 
Gln72Oε1 βPhe53N 1 5 
Gln72Nε2 βGly54O  1 1 
Gln72 βIle56  2 
Thr73 βGly97  1 1 
Arg75 βPhe53  2 15 
Val76 βAsn30  1 
Val76 βPhe53  2 
Glu154Oε1/Oε2 αTyr51OH 2 7 
Gln155 αTyr51  4 
Gln155 βGly99  1 
Gln155H2O βMet100H2O 1 2 
Ala158 αTyr51  2 
Tyr159 αGln31  1 
Thr163H2O αGln31H2O 1 2 
Trp167 αLeu28  4 
Trp167 αGly29  2 
Arg170 αLeu28  3 
 
  
Supplementary Table S5: α24β17-A2-ELA7A contacts (7A peptide contacts shown in red) 
 
Peptide  TCR  H-bonds H-bonds vdW vdW 
Glu1Oε2 αGly29O  1 1 1 
Glu1Oε2 αGln31Nε2 1 1 
Leu2O αGln31Nε2 1 2 
Ala3 αGln31  4 
Ala3 βLeu98  1  
Gly4N αGln31Oε1 1 2 3 
Gly4 βLeu98  2 
Ile5 βLeu98  1 1 
Ala6N βLeu98O 1 2 
Ala7 βGly97  2 
Ala7N/O βLeu98O/N 2 6 
Leu8 βThr96  1 
Leu8 βLeu98  1 
Leu8 βGly99  1 
Thr9 βThr96  1 1 
MHC  TCR  H-bonds H-bonds vdW vdW 
Arg44H2O βSer58H2O 1    
Glu58 αPhe27  4 
Gly62 αAsp93  1 
Arg65 βIle56  2 
Arg65H2O βSer58H2O/H2O 2  
Arg65NH2 αAsp93O 1 3 
Arg65Nε αGly94O 1 1 3 
Arg65 αArg96  1 6 
Lys66 αGly94  2 
Lys66 αLeu98  1 
Lys68 βIle56  1 
Ala69 βTyr49  1 
Ala69 βLeu98  1  
His70 βLeu98  1 
Gln72 βGly51  2 1 
Gln72Oε1 βPro52N 1 1 3 
Gln72Oε1 βPhe53N 1 8 
Gln72Nε1 βGly54O 1 4 
Gln72 βIle56  2 
Arg75 βPhe53  1 13 
Val76 βAsn30  1 
Val76 βPhe53  1 1 
Glu154 αTyr51  3 
Gln155 αTyr51  3 
Gln155 βGly99  1 
Gln155H2O βMet100H2O 1 3 
Ala158 αTyr51  2 
Tyr159 αGln31  1 
Thr163H2O αGln31H2O 1 3 
Trp167 αGly29  2 
Arg170 αLeu28  1 1 
 
  
Supplementary Table S6. Data collection and refinement statistics for A2-ELA peptide alanine 
substitution structures (molecular replacement). 
 
 A2-ELA1A A2-ELA4A A2-ELA8A 
PDB Code 4JFO 4JFP 4JFQ 
Data collection    
Space group P1 C121 P1211 
Cell dimensions    
    a, b, c (Å) 50.28, 63.26, 75.10, 202.59, 49.11, 117.6 84.1, 58.36, 89.43 
()  81.96, 76.09, 77.98 90, 90, 123 90, 109.8, 90 
Resolution (Å) 45.2-2.2 (7.3-2.1) 39.7 - 2.0 (8.6-1.9) 58.6-2.0 (9.4-1.9) 
Rmerge (%) 10.0 5.2  7.0  
I /  18.9 10.7  16.5 
Completeness (%) 78.8 98.0  97.0  
Redundancy 2.1 3.5  3.4 
    
Refinement    
Resolution (Å) 2.1 1.9 1.9 
No. reflections 40179 70233 61271 
Rwork / Rfree 21.8/29.6 20.5/23.9 21.9/29.6 
No. atoms 6715 7089 7301 
    Protein 6304 6561 6378 
    Ligand/ion 65 101 138 
    Water 346 427 785 
B-factors 30.33 39.41 19.30 
    Protein 29.96 38.79 18.12 
    Ligand/ion 45.03 59.33 35.14 
    Water 34.34 44.25 26.06 
R.m.s. deviations    
    Bond lengths (Å) 0.021 0.026  0.20 
    Bond angles () 1.497 1.688 1.845 
* One crystal was used for solving each structure.  
*Values in parentheses are for highest-resolution shell. 
  
Supplementary Figures: 
 
 
Supplementary Figure S1: 2Fo-Fc electron density maps for all structures reported 
2Fo-Fc electron density maps (shown in cyan) for (A) α24β17 free (CDR3 loops are shown), (B) α24β17-
A2-ELA complex (CDR3 loops and peptide are shown), (C) α24β17-A2-ELA4A complex (CDR3 loops 
and peptide are shown), (D) α24β17-A2-ELA7A complex (CDR3 loops and peptide are shown), (E) A2-
ELA1A, (F) A2-ELA4A and (G) A2-ELA8A. All maps shown are within 2Å from the atoms to which 
they relate. Positive density is shown in green and negative density is shown in red. 
  
  
Supplementary Figure S2: Structural differences between the MEL5 versus α24β17 when 
interacting with A2-ELA. 
(A) The α24β17 (cyan) and MEL5 (green) crossing angles when interacting with A2-ELA (grey surface 
and cartoon, peptide shown as yellow sticks). (B) Positions of the α24β17 TCR CDR loops when 
interacting with A2-ELA (cyan cartoon) are similar, but not identical to the positions of the MEL5 TCR 
CDR loops (green cartoon) when binding to A2-ELA. (C&D) The ELAGIGILTV peptide does not 
undergo any substantial structural changes when in complex with MEL5 (yellow) compared to α24β17 
(red). (C) Top view of the MEL5 and α24β17 complexed ELA peptide. (D) Side view the MEL5 and 
α24β17 complexed ELA peptide. 
  
 Supplementary Figure S3. α24β17 is extremely sensitive to alanine substitutions within the 
ELAGIGILTV peptide.  
Ten serial dilutions of α24β17 were measured in four separate experiments (with different protein 
preparations) for each alanine substituted peptide; representative data from these experiments are plotted. 
The response units at each concentration of the TCR were taken from the point shown by the vertical line 
in each of the insets (40 seconds into the 60 second injection). Alanine substitutions in any position 
within the peptide reduced binding from 600pM down to wildtype like affinities (μM). The equilibrium 
binding constant (KD) values were calculated using a nonlinear curve fit (y= (P1x)/P2 + x)); mean plus SD 
values are shown. In order to calculate each response, α24β17 was also injected over a control sample 
(HLA-A*0201 in complex with ILAKFLHWL peptide, or HLA-DR1) that was deducted from the 
experimental data. (A) α24β17 binding to ALAGIGILTV (B) α24β17 binding to ELAAIGILTV (C) 
α24β17 binding to ELAGIAILTV (D) α24β17 binding to ELAGIGALTV (E) α24β17 binding to 
ELAGIGIATV (F) α24β17 binding to ELAGIGILAV. We observed no signal for α24β17 binding to 
ELAGAGILTV (data not shown).  
 Supplementary Figure S4. Alanine substitutions do not alter the overall conformation of the 
unligated A2-ELA related pMHCs. 
Structural comparison of the A2-ELA unligated crystal structure (1JF1)1 with: (A) A2-ELA from the 
α24β17-A2-ELA complex structure, (B) A2-ELA1A, (C) A2-ELA4A and (D) A2-ELA8A. These 
structures show that the conformation of the peptide backbone is not altered by TCR binding, or by 
alanine substitutions. Furthermore, the positions of the solvent exposed side chains is virtually identical in 
all of the structures, showing that large alterations in peptide conformation in unligated state cannot 
account for the difference in binding affinity observed between α24β17 binding to A2-ELA compared to 
the alanine substituted peptides.  
  
 Supplementary Figure S5. Thermodynamic analysis of the α24β17-A2-ELA interaction. 
Kinetic titration analysis was used to determine the affinity of the α24β17-A2-ELA interaction at: (A) 
5°C, (B) 7°C, (C) 12°C, (D) 15°C, (E) 19°C, (F) 22°C, (G) 25°C, (H) 30°C, (I) 32°C, (J) 35°C, (K) 37°C 
and (L) 40°C. Each step in the graph indicates an injection of α24β17 using 3X increase in concentration. 
Thus, the five injections of α24β17 were performed at 10nM, 31nM, 94nM, 283nM, and 850nM. The raw 
data and the fits are shown in each panel. These data were used to fit thermodynamic parameters shown in 
Figure 6. 
 Supplementary Figure S6. Thermodynamic analysis of the α24β17-A2-ELA4A interaction. 
Ten serial dilutions of α24β17 were measured in triplicate at each temperature; representative data from 
these experiments are plotted. The response units at each concentration of the TCR were taken from the 
point shown by the vertical line in each of the insets (40 seconds into the 60 second injection). The 
equilibrium binding constant (KD) values were calculated using a nonlinear curve fit (y= (P1x)/P2 + x)); 
mean plus SD values are shown. (A) 5°C, (B) 13°C, (C) 15°C, (D) 20°C, (E) 25°C and (F) 30°C. These 
data were used to fit thermodynamic parameters shown in Figure 6.  
 Supplementary Figure S7. Thermodynamic analysis of the α24β17-A2-ELA7A interaction. 
Ten serial dilutions of α24β17 were measured in triplicate at each temperature; representative data from 
these experiments are plotted. The response units at each concentration of the TCR were taken from the 
point shown by the vertical line in each of the insets (40 seconds into the 60 second injection). The 
equilibrium binding constant (KD) values were calculated using a nonlinear curve fit (y= (P1x)/P2 + x)); 
mean plus SD values are shown. (A) 5°C, (B) 13°C, (C) 15°C, (D) 20°C and (E) 25°C. These data were 
used to fit thermodynamic parameters shown in Figure 6. 
  
  
Supplementary Figure S8: α24β17 undergoes large TCR CDR movement during ligand 
engagement. 
Comparison of the conformation of the α24β17 TCR CDR1, CDR2 and CDR3 loops in the α24β17-A2-
ELA complex (α24β17lig) versus α24β17 unligated (α24β17free). (A) Superposition of the free (purple 
cartoon) and complexed (cyan cartoon) TCRs. (B) Superposition of the free (purple lines) and complexed 
(cyan lines) α24β17 TCR looking down on the peptide (yellow sticks). (C) Superposition of the free 
(purple lines) and complexed (cyan cartoon) α24β17 CDR1α, CDR3α, CDR2β and CDR3β loops from 
the side. The CDR3β loop has to move in order to avoid a clash with the peptide (yellow sticks) during 
binding. (D) Superposition of the free (purple lines) and complexed (cyan lines) α24β17 TCR CDR loops 
during binding showing backbone shifts in Å (orientation as in (B)). The CDR2β and CDR3β loops 
undergoes the largest conformational change upon binding. 
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